← ANALYST RATINGS · TIPRANKS
Pharming Group (PHAR): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $37.50, the highest $38.00, the lowest $37.00. The average is +300.6% from the last price of $9.36.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $38.00 | Buy | +306.0% | Reiterated | 14.10.26on TipRanks Oct 15 07:30 | +3.2%next day −0.4% | ↗ |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $37.00 | Buy | +295.3% | Reiterated | 14.10.26on TipRanks 10:31 | +3.2%next day −0.4% | ↗ |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $10.50 → $10.00−4.8% | Hold | +6.8% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.00 | Hold | +28.2% | Reiterated | 23.09.26on TipRanks 06:07 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.50 | Hold | +22.9% | Reiterated | 23.09.26on TipRanks 06:07 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $11.50 | Hold | +22.9% | Reiterated | 23.09.26on TipRanks 06:07 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $11.00 | Hold | +17.5% | Reiterated | 23.09.26on TipRanks 06:07 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $11.50 | Hold | +22.9% | Reiterated | 23.09.26on TipRanks 06:07 | — | |
| Jeff Jones★★★★★★★★★★#749 · hits 46% · avg +20.3% | Oppenheimer | $41.00 → $40.00−2.4% | Buy | +327.4% | Reiterated | 08.05.26on TipRanks 08:45 | +7.3%next day −3.0% · 5 days −0.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Pharming Group
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $37.50 at a price of $9.99 (+275.4%); now: $37.50 at $9.36 (+300.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 7 | 8 | 6 | 9 | 9 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.16 (from $0.02 to $0.30). Last quarter: $0.02.
Sales
Next quarter’s sales estimate — $104M (from $98M to $108M). Last quarter: $90M.
Best top-analyst consensus in the sector · Healthcare
About Pharming Group
- CEO: Fabrice Chouraqui
- Employees: 407
- Darwinweg 24, Leiden, ZH, 2333 CR, NL
- www.pharming.com
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Data from the stock’s TipRanks forecast page, read 34 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗